Acro Biomedical Co., Ltd. (ACBM) stock
Close on Oct 19, 2026Market cap $1.56MP/E –Yield –
Acro Biomedical Co., Ltd. reported revenue of $0 for the twelve months to Jun 30, 2026. At the latest close the market valued the company at $1.56M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.56M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$140.41K
- EPS, diluted
- $0.00
- Book value per share
- -$0.01
- Diluted shares
- 60M
Trading
- Previous close
- $0.03
- Open
- $0.03
- Day's range
- $0.03 – $0.03
- Volume
- 0
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | ACBM | S&P 500 | Difference | ACBM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | 0.0% | +0.6% | −0.6 pts | ||
| 3 months | 0.0% | +3.4% | −3.4 pts | ||
| Year to date | +17.1% | +13.3% | +3.8 pts | ||
| 1 year | +3614.3% | +16.6% | +3597.7 pts | ||
| 3 years | -98.3% | +86.4% | −184.6 pts | -74.1% | +23.1% |
| 5 years | -99.4% | +81.9% | −181.3 pts | -64.3% | +12.7% |
Eleven years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
About Acro Biomedical
Services-Amusement & Recreation Services
Acro Biomedical Co., Ltd., formerly known as Killer Waves Hawaii, Inc., develops and markets nutritional wellness products centered on cordyceps, a parasitic fungus traditionally utilized in Chinese medicine. Historically, the company has purchased inventory from suppliers in Taiwan to sell in bulk to commercial customers, including distributors. These clients either resell the products directly or incorporate them as ingredients into finished goods. The company has also previously sold metallothionein MT-3 elizer and explored developing cordyceps-based chicken feed, though it does not package or offer items directly for retail consumer use.
Company profile, executives and historyAcro Biomedical stock: common questions
What is Acro Biomedical's stock price?
ACBM closed at $0.03 on Oct 19, 2026, up 0.00% on the day.
What is Acro Biomedical's market cap?
Acro Biomedical was worth $1.56M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is ACBM's P/E ratio?
Acro Biomedical lost money over the twelve months to Jun 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.
How much revenue does Acro Biomedical make?
Acro Biomedical reported revenue of $0 for the twelve months to Jun 30, 2026.
Does Acro Biomedical pay a dividend?
No. Acro Biomedical has not paid a cash dividend over the last twelve months.
How has ACBM stock performed over the past year?
Including dividends, ACBM returned +3614.3% over the past year, against +16.6% for the S&P 500.
Who are Acro Biomedical's competitors?
Companies most similar to Acro Biomedical by business, industry and size include LAAI, TONT, LVRLF, CPOP, FLZH.
See a number that looks wrong?